S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
The "King Of Quants" sees 10X potential... (Ad)
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Closing prices for crude oil, gold and other commodities
The "King Of Quants" sees 10X potential... (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
The "King Of Quants" sees 10X potential... (Ad)
The Bottom Is In For Accenture
14 Best Consumer Staples Dividend Stocks
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
The "King Of Quants" sees 10X potential... (Ad)
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Closing prices for crude oil, gold and other commodities
The "King Of Quants" sees 10X potential... (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
The "King Of Quants" sees 10X potential... (Ad)
The Bottom Is In For Accenture
14 Best Consumer Staples Dividend Stocks
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
The "King Of Quants" sees 10X potential... (Ad)
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Closing prices for crude oil, gold and other commodities
The "King Of Quants" sees 10X potential... (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
The "King Of Quants" sees 10X potential... (Ad)
The Bottom Is In For Accenture
14 Best Consumer Staples Dividend Stocks
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
The "King Of Quants" sees 10X potential... (Ad)
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Closing prices for crude oil, gold and other commodities
The "King Of Quants" sees 10X potential... (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
The "King Of Quants" sees 10X potential... (Ad)
The Bottom Is In For Accenture
14 Best Consumer Staples Dividend Stocks
NASDAQ:ARVN

Arvinas - ARVN Competitors

$26.45
+0.11 (+0.42%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$25.35
$26.51
50-Day Range
$26.34
$37.26
52-Week Range
$25.35
$75.39
Volume
570,340 shs
Average Volume
506,620 shs
Market Capitalization
$1.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.75

ARVN vs. VRNA, SNDX, CVAC, MORF, KDNY, PLRX, RNA, NUVL, RCKT, and IRWD

Should you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Verona Pharma (VRNA), Syndax Pharmaceuticals (SNDX), CureVac (CVAC), Morphic (MORF), Chinook Therapeutics (KDNY), Pliant Therapeutics (PLRX), Avidity Biosciences (RNA), Nuvalent (NUVL), Rocket Pharmaceuticals (RCKT), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.

Arvinas vs.

Arvinas (NASDAQ:ARVN) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Verona Pharma has lower revenue, but higher earnings than Arvinas. Verona Pharma is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$131.40 million10.72-$282.50 million-$5.32-4.97
Verona Pharma$460 thousand3,391.39-$68.70 million-$1.12-18.42

Arvinas currently has a consensus target price of $68.75, indicating a potential upside of 159.92%. Verona Pharma has a consensus target price of $29.33, indicating a potential upside of 42.19%. Given Arvinas' higher possible upside, equities analysts clearly believe Arvinas is more favorable than Verona Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arvinas
0 Sell rating(s)
5 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.72
Verona Pharma
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

92.0% of Arvinas shares are held by institutional investors. 2.8% of Arvinas shares are held by insiders. Comparatively, 3.9% of Verona Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Arvinas has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500.

In the previous week, Arvinas had 2 more articles in the media than Verona Pharma. MarketBeat recorded 6 mentions for Arvinas and 4 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 0.36 beat Arvinas' score of 0.17 indicating that Verona Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arvinas
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Verona Pharma
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Verona Pharma received 152 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 79.68% of users gave Verona Pharma an outperform vote while only 63.48% of users gave Arvinas an outperform vote.

CompanyUnderperformOutperform
ArvinasOutperform Votes
146
63.48%
Underperform Votes
84
36.52%
Verona PharmaOutperform Votes
298
79.68%
Underperform Votes
76
20.32%

Verona Pharma has a net margin of 0.00% compared to Arvinas' net margin of -228.19%. Verona Pharma's return on equity of -38.97% beat Arvinas' return on equity.

Company Net Margins Return on Equity Return on Assets
Arvinas -228.19% -43.79% -20.55%
Verona Pharma N/A -38.97% -32.01%

Summary

Verona Pharma beats Arvinas on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARVN vs. The Competition

MetricArvinasPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.41B$5.52B$4.34B$5.90B
Dividend YieldN/A2.59%2.39%4.41%
P/E Ratio-4.979.75152.7215.51
Price / Sales10.72316.603,468.0360.90
Price / CashN/A19.7427.39103.34
Price / Book2.494.184.464.95
Net Income-$282.50M$186.18M$115.01M$190.72M
7 Day Performance-11.69%-1.27%-0.87%0.57%
1 Month Performance-17.29%-8.33%-6.65%-5.99%
1 Year Performance-60.22%-15.00%-16.56%-18.82%

Arvinas Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRNA
Verona Pharma
1.9876 of 5 stars
$19.51
-0.5%
$29.33
+50.4%
+296.0%$1.48B$460,000.00-17.4224
SNDX
Syndax Pharmaceuticals
2.4368 of 5 stars
$21.46
-7.0%
$33.57
+56.4%
+21.1%$1.47B$139.71M-8.7659
CVAC
CureVac
2.2112 of 5 stars
$6.50
-6.2%
$24.33
+274.4%
-66.8%$1.44B$115.57M0.00455
MORF
Morphic
2.3132 of 5 stars
$38.47
-4.6%
$65.71
+70.8%
-13.1%$1.52B$70.81M-24.19101
KDNY
Chinook Therapeutics
2.4854 of 5 stars
$21.53
-2.0%
$38.00
+76.5%
+41.6%$1.42B$6.13M-7.48138Positive News
PLRX
Pliant Therapeutics
2.6368 of 5 stars
$26.11
-5.1%
$46.70
+78.9%
+240.4%$1.54B$9.69M-8.7991Analyst Revision
RNA
Avidity Biosciences
1.4655 of 5 stars
$19.56
-5.3%
$44.60
+128.0%
+10.5%$1.39B$9.22M-5.87125
NUVL
Nuvalent
1.5897 of 5 stars
$27.87
-5.2%
$44.50
+59.7%
+114.4%$1.57BN/A-16.9940News Coverage
RCKT
Rocket Pharmaceuticals
2.6466 of 5 stars
$17.13
-4.1%
$52.58
+207.0%
+4.1%$1.36BN/A-5.21151News Coverage
IRWD
Ironwood Pharmaceuticals
2.1386 of 5 stars
$10.42
-1.6%
$14.67
+40.8%
-16.2%$1.61B$410.60M10.74219Positive News
This page (NASDAQ:ARVN) was last updated on 3/25/2023 by MarketBeat.com Staff